Peptide drug development has made great progress in the last decade thanks to new
production, modification, and analytic technologies. Peptides have been produced and …

As one of the most successful therapeutic target families, G protein-coupled receptors
(GPCRs) have experienced a transformation from random ligand screening to knowledge …

Almost all currently available treatments for inflammatory bowel disease (IBD) act by
inhibiting inflammation, often blocking specific inflammatory molecules. However, given the …

A large proportion of protein–protein interactions (PPIs) occur between a short peptide and a
globular protein domain; the peptides involved in surface interactions play important roles …

Despite unequivocal roles in disease, transcription factors (TFs) remain largely untapped as
pharmacologic targets due to the challenges in targeting protein–protein and protein–DNA …

Inflammatory bowel disease (IBD) is a group of disorders that cause chronic non-specific
inflammation in the gastrointestinal (GI) tract, primarily affecting the ileum and colon. The …

Peptides are a rapid-growing class of therapeutics with unique and desirable
physicochemical properties. Due to disadvantages such as low membrane permeability and …

Biomacromolecules have long been at the leading edge of academic and pharmaceutical
drug development and clinical translation. With the clinical advances of new therapeutics …

Psoriasis is one of the most common inflammatory skin diseases affecting about 1–3% of the
population. One of the characteristic abnormalities in psoriasis is the excessive production of …

Inflammatory bowel disease (IBD) is a comprehensive term for chronic or relapsing
inflammatory diseases occurring in the intestinal tract, generally including Crohn's disease …